Serum Tumor Markers for Detection of Bone Metastasis in Breast Cancer Patients

References

• Barry W F, Wells S A, Cox C E. Clinical and radiographic correlations in breast cancer patients with osseous metastases. Skeletal Radiol 1981; 6: 27–32
   PubMed Web of Science ®Google Scholar
• Viadana E, Bross I DJ, Pickren J W. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 1973; 27: 336–40
   PubMedGoogle Scholar
• Hegemeister F B, Buzdar A U, Luna M A, Blumenschein G R. Causes of death in breast cancer. A clinicopathologic study. Cancer 1980; 46: 162–7
   PubMedGoogle Scholar
• Lee Y TN. Breast carcinoma: Pattern of recurrence and metastasis after mastectomy. Am J Clin Pathol 1984; 7: 443–9
   Google Scholar
• Robbins G F, Knapper W H, Barne J, Kripalani I, Lawrence J. Metastatic bone disease developing in patients with potentially curable breast cancer. Cancer 1972; 29: 1702–4
   PubMedGoogle Scholar
• Thomsen H S, Lund J O, Munck O, Andersen K W, Stockel M, Rossing N. Bone metastases in primary operable breast cancer. The role of serial scintigraphy. Eur J Cancer Clin Oncol 1984; 20: 1019–23
   PubMedGoogle Scholar
• Hortobagyi G N, Libshitz H I, Seabold J E. Osseous metastases of breast cancer: Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 1984; 53: 577–82
   PubMedGoogle Scholar
• Schinozaki T, Chigira M, Kato K. Multivariate analyses of serum tumor markers for diagnosis of skeletal metastases. Cancer 1992; 69: 108–12
   PubMedGoogle Scholar
• Kamby C, Vejborg I, Daugaard S. Clinical and radio-logic characteristics of bone metastases in breast cancer. Cancer 1987; 60: 2524–31
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N. Bone metastases in breast cancer patients. Semin Oncol 1991; 18(Suppl. 5)11–5
   PubMedGoogle Scholar
• Yazawa Y, Frassica F J, Chao E YS, Pritchard D J, Sim F H, Shieves T H. Metastatic bone disease: A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop 1990; 251: 213–9
   Google Scholar
• Tondini C, Hayes D F, Gelman R, Henderson I C, Kafe D W. Comparison of CA 15–3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107–12
   PubMed Web of Science ®Google Scholar
• Coleman R E, Whitaker K B, Moss D W. Biochemical prediction response of bone metastases to treatment. Br J Cancer 1988; 58: 205–10
   PubMed Web of Science ®Google Scholar
• Kreienberg R. Droloxifene-induced spikes of tumor markers predict benefit of therapy. Am J Clin Oncol 1991; 14(Suppl. 2)56–61
   Google Scholar
• Johnson R A, Wichern D W. Applied multivariate statistical analysis. Prentice-Hall Inc., Englewood 1982; 461–541
   Google Scholar
• Morrison F D. Multivariate statistical methods. McGraw-Hill International Book Company, Tokyo 1978; 230–3
   Google Scholar
• Cassuto J P, Krebs B P, Viot G, Dujardin P, Masseyeff R. β2-microglobulin—a tumor marker of lymphoproliferative disorders. Lancet 1978; 2: 108–9
   PubMed Web of Science ®Google Scholar
• Abelev G I. Alpha-fetoprotein in ontogenesis and in association with malignant tumors. Adv Cancer Res 1971; 14: 295–358
   PubMedGoogle Scholar
• Bast B C, Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
   PubMed Web of Science ®Google Scholar
• Robertson J F, Pearson D, Price M R. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 1991; 33: 403–10
   PubMed Web of Science ®Google Scholar
• Hayes D F, Zurawski V R, Kufe D W. Comparison of circulating CA 15–3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542–50
   PubMed Web of Science ®Google Scholar
• Klein B, Klein T, Figer A. Soluble histocompatibility antigen class I in breast cancer patients in relation to tumor burden. Cancer 1991; 67: 2295–9
   PubMedGoogle Scholar
• Giglio A, Franco E L, Torloni H. Tumor and serum beta-2-microglobulin expression in women with breast cancer. Am J Clin Pathol 1989; 92: 339–43
   PubMedGoogle Scholar
• Williams M R, Turkes A, Pearson D, Griffiths K, Blarney R W. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer. Eur J Surg Oncol 1990; 16: 22–7
   PubMedGoogle Scholar
• Björklund B, Björklund V. Specificity and basis of the tissue polypeptide antigen. Cancer Detect Prev 1983; 6: 41–50
   PubMedGoogle Scholar
• Dalen A. TPS in breast cancer—A comparative study with carcinoembryonic antigen and CA 15–3. Tumor Biol 1992; 13: 10–7
   PubMedGoogle Scholar
• Chigira M, Shinozaki T, Shimizu T, Noda K. No correlation between tumor markers and prognosis under polygenic control system. Med Hypotheses 1990; 32: 245–8
   PubMedGoogle Scholar
• Killion J J, Fidler I J. The biology of tumor metastasis. Semin Oncol 1989; 16: 106–16
   PubMedGoogle Scholar